We use cookies to ensure that we give you the best experience on our website Learn more

Jun 4, 2019

PTCOG58

09 - Preliminary results of pencil beam scanning proton and carbon ion therapy for skull base and cervical spine chordoma and chondrosarcoma

;

chondrosarcoma

chordoma

radiotherapy

proton

carbon ion

Abstract

Abstract

thumbnail

Keywords

chondrosarcoma

chordoma

radiotherapy

proton

carbon ion

Abstract

Purpose: to evaluate the short-term outcomes in terms of tumor control and toxicity of patients with skull base or cervical spine chordoma and chondrosarcoma treated with intensity-modulated proton or carbon-ion radiation therapy. Methods: Between 6/2014 and 7/2018, a total of 91 patients were treated with proton and/or carbon ion radiotherapy at the Shanghai Proton and Heavy Ion Center. The median age was 38 (range, 4-70) years. Forty-six (50.5%) patients were treated definitively for their conditions as initial diagnosis, 45 (49.5%) patients had recurrent tumors including 14 had prior radiotherapy. The median gross tumor volume was 37.0 (range, 1.6-231.7) cc. Eight patients received proton therapy alone, 28 patients received combined proton and carbon ion therapy, 55 patients received carbon-ion therapy alone. Results: With a median follow-up time of 28 (range, 8-59) months, the 2-year local control (LC), progression free (PFS) and overall survival (OS) rates was 86.2%, 76.8%, and 87.2%, respectively. Those rates for patients received definitive proton or carbon-ion therapy were 86.7%, 82.8%, and 93.8%, respectively. On multivariate analyses, tumor volume of > 60cc was the only significant factor for predicting PFS (p=0.045), while re-irradiation (p=0.012) and tumor volume (> vs < 60cc) (p=0.005) were significant prognosticators for OS. Grade 1-2 late toxicities were observed in 11 patients, and one patient developed Grade 3 acute mucositis. No grade 4 or 5 toxicities were observed. Conclusions: Proton and/or carbon-ion radiotherapy produced favorable disease control and minimal treatment associated adverse effects for patients with skull base or cervical chordoma and chondrosarcoma. Larger tumor volume and re-irradiation were related to inferior survival for this group of patients. Further follow-up is needed for long-term efficacy and safety.

Discover over 20,000 new abstracts, posters and presentations from leading academic conferences every month. Stay on top of the latest findings, methodologies and discussions happening in your research field around the world.

Company

Legal

Follow us

© Copyright 2019 Morressier GmbH. All rights reserved.

© Copyright 2019 Morressier GmbH.
All rights reserved.